Ultrasound treatment of sub-dermal tissue for cosmetic effects

Information

  • Patent Grant
  • 8506486
  • Patent Number
    8,506,486
  • Date Filed
    Friday, November 16, 2012
    12 years ago
  • Date Issued
    Tuesday, August 13, 2013
    11 years ago
Abstract
A method and system for noninvasive face lifts and tissue tightening are disclosed. The method and treatment system are configured for thermal treatment of Superficial Muscular Aponeurosis System (SMAS) tissue, muscular fascia, or both. In one embodiment, a cosmetic system is configured for treating the SMAS and/or muscular fasica through delivery of ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect.
Description
BACKGROUND

1. Field of the Invention


The present invention relates to ultrasound therapy and imaging systems, and in particular to a method and system for noninvasive face lifts and deep tissue tightening.


2. Description of the Related Art


Coarse sagging of the skin and facial musculature occurs gradually over time due to gravity and chronic changes in connective tissue generally associated with aging. Invasive surgical treatment to tighten such tissues is common, for example by facelift procedures. In these treatments for connective tissue sagging, a portion of the tissue is usually removed, and sutures or other fasteners are used to suspend the sagging tissue structures. On the face, the Superficial Muscular Aponeurosis System (SMAS) forms a continuous layer superficial to the muscles of facial expression and beneath the skin and subcutaneous fat. Conventional face lift operations involve suspension of the SMAS through such suture and fastener procedures.


No present procedures have been developed yet, which provide the combination of targeted, precise, local heating to a specified temperature region capable of inducing ablation (thermal injury) to underlying skin and subcutaneous fat. Attempts have included the use of radio frequency (RF) devices that have been used to produce heating and shrinkage of skin on the face with some limited success as a non-invasive alternative to surgical lifting procedures. However, RF is a dispersive form of energy deposition. RF energy is impossible to control precisely within the heated tissue volume and depth, because resistive heating of tissues by RF energy occurs along the entire path of electrical conduction through tissues. Another restriction of RF energy for non-invasive tightening of the SMAS is unwanted destruction of the overlying fat and skin layers. The electric impedance to RF within fat, overlying the suspensory connective structures intended for shrinking, leads to higher temperatures in the fat than in the target suspensory structures. Similarly, mid-infrared lasers and other light sources have been used to non-invasively heat and shrink connective tissues of the dermis, again with limited success. However, light is not capable of non-invasive treatment of SMAS because light does not penetrate deeply enough to produce local heating there. Below a depth of approximately 1 mm, light energy is multiply scattered and cannot be focused to achieve precise local heating.


SUMMARY OF THE INVENTION

A method and system for noninvasive face lifts and deep tissue tightening are provided. An exemplary method and treatment system are configured for the imaging, monitoring, and thermal injury to treat the SMAS region. In accordance with an exemplary embodiment, the exemplary method and system are configured for treating the SMAS region by first, imaging of the region of interest for localization of the treatment area and surrounding structures, second, delivery of ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect, and third to monitor the treatment area before, during, and after therapy to plan and assess the results and/or provide feedback.


In accordance with an exemplary embodiment, an exemplary treatment system comprises an imaging/therapy probe, a control system and display system. The imaging/therapy probe can comprise various probe and/or transducer configurations. For example, the probe can be configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, or simply a therapy probe and an imaging probe. The control system and display system can also comprise various configurations for controlling probe and system functionality, including for example a microprocessor with software and a plurality of input/output devices, a system for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or transducers, and systems for handling user input and recording treatment results, among others.


In accordance with an exemplary embodiment, ultrasound imaging can be utilized for safety purposes, such as to avoid injuring vital structures such as the facial nerve (motor nerve), parotid gland, facial artery, and trigeminal nerve (for sensory functions) among others. For example, ultrasound imaging can be used to identify SMAS as the superficial layer well defined by echoes overlying the facial muscles. Such muscles can be readily seen and better identified by moving them, and their image may be further enhanced via signal and image processing.


In accordance with an exemplary embodiment, ultrasound therapy via focused ultrasound, an array of foci, a locus of foci, a line focus, and/or diffraction patterns from single element, multiple elements, annular array, one-, two-, or three-dimensional arrays, broadband transducers, and/or combinations thereof, with or without lenses, acoustic components, mechanical and/or electronic focusing are utilized to treat the SMAS region at fixed and/or variable depth or dynamically controllable depths and positions.





BRIEF DESCRIPTION OF THE DRAWINGS

The subject matter of the invention is particularly pointed out in the concluding portion of the specification. The invention, however, both as to organization and method of operation, may best be understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals:



FIG. 1 illustrates a block diagram of a treatment system in accordance with an exemplary embodiment of the present invention;



FIGS. 2A-2F illustrates schematic diagrams of an ultrasound imaging/therapy and monitoring system for treating the SMAS layer in accordance with various exemplary embodiments of the present invention;



FIGS. 3A and 3B illustrate block diagrams of an exemplary control system in accordance with exemplary embodiments of the present invention;



FIGS. 4A and 4B illustrate block diagrams of an exemplary probe system in accordance with exemplary embodiments of the present invention;



FIG. 5 illustrates a cross-sectional diagram of an exemplary transducer in accordance with an exemplary embodiment of the present invention;



FIGS. 6A and 6B illustrate cross-sectional diagrams of an exemplary transducer in accordance with exemplary embodiments of the present invention;



FIG. 7 illustrates exemplary transducer configurations for ultrasound treatment in accordance with various exemplary embodiments of the present invention;



FIGS. 8A and 8B illustrate cross-sectional diagrams of an exemplary transducer in accordance with another exemplary embodiment of the present invention;



FIG. 9 illustrates an exemplary transducer configured as a two-dimensional array for ultrasound treatment in accordance with an exemplary embodiment of the present invention;



FIGS. 10A-10F illustrate cross-sectional diagrams of exemplary transducers in accordance with other exemplary embodiments of the present invention;



FIG. 11 illustrates a schematic diagram of an acoustic coupling and cooling system in accordance with an exemplary embodiment of the present invention;



FIG. 12 illustrates a block diagram of a treatment system comprising an ultrasound treatment subsystem combined with additional subsystems and methods of treatment monitoring and/or treatment imaging as well as a secondary treatment subsystem in accordance with an exemplary embodiment of the present invention; and



FIG. 13 illustrates a schematic diagram with imaging, therapy, or monitoring being provided with one or more active or passive oral inserts in accordance with an exemplary embodiment of the present invention.





DETAILED DESCRIPTION

The present invention may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, the present invention may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions under the control of one or more control systems or other control devices. In addition, the present invention may be practiced in any number of medical contexts and that the exemplary embodiments relating to a method and system for noninvasive face lift and deep tissue tightening as described herein are merely indicative of exemplary applications for the invention. For example, the principles, features and methods discussed may be applied to any SMAS-like muscular fascia, such as platysma, temporal fascia, and/or occipital fascia, or any other medical application. Further, various aspects of the present invention may be suitably applied to other applications.


In accordance with various aspects of the present invention, a method and system for noninvasive face lifts and deep tissue tightening are provided. For example, in accordance with an exemplary embodiment, with reference to FIG. 1, an exemplary treatment system 100 configured to treat a region of interest 106 comprises a control system 102, an imaging/therapy probe with acoustic coupling 104, and a display system 108. Control system 102 and display system 108 can comprise various configurations for controlling probe 102 and overall system 100 functionality, such as, for example, a microprocessor with software and a plurality of input/output devices, system and devices for controlling electronic and/or mechanical scanning and/or multiplexing of transducers, a system for power delivery, systems for monitoring, systems for sensing the spatial position of the probe and/or transducers, and/or systems for handling user input and recording treatment results, among others. Imaging/therapy probe 104 can comprise various probe and/or transducer configurations. For example, probe 104 can be configured for a combined dual-mode imaging/therapy transducer, coupled or co-housed imaging/therapy transducers, or simply a separate therapy probe and an imaging probe.


In accordance with an exemplary embodiment, treatment system 100 is configured for treating the SMAS region by first, imaging of region of interest 106 for localization of the treatment area and surrounding structures, second, delivery of ultrasound energy at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect, and third to monitor the treatment area before, during, and after therapy to plan and assess the results and/or provide feedback.


As to the treatment of the SMAS region, connective tissue can be permanently tightened by thermal treatment to temperatures about 60 degrees C. or higher. Upon ablating, collagen fibers shrink immediately by approximately 30% of their length. The shrunken fibers can produce tightening of the tissue, wherein the shrinkage should occur along the dominant direction of the collagen fibers. Throughout the body, collagen fibers are laid down in connective tissues along the lines of chronic stress (tension). On the aged face, the collagen fibers of the SMAS region are predominantly oriented along the lines of gravitational tension. Shrinkage of these fibers results in tightening of the SMAS in the direction desired for correction of laxity and sagging due to aging. The treatment comprises the ablation of specific regions of the SMAS region and similar suspensory connective tissues.


In addition, the SMAS region varies in depth and thickness at different locations, e.g., between 0.5 mm to 5 mm or more. On the face, important structures such as nerves, parotid gland, arteries and veins are present over, under or near the SMAS region. Tightening of the SMAS in certain locations, such as the preauricular region associated with sagging of the cheek to create jowls, the frontal region to associated with sagging brows, mandibular region associated with sagging neck, can be conducted. Treating through localized heating of regions of the SMAS or other suspensory subcutaneous connective tissue structures to temperatures of about 60-90° C., without significant damage to overlying or distal/underlying tissue, i.e., proximal tissue, as well as the precise delivery of therapeutic energy to SMAS regions, and obtaining feedback from the region of interest before, during, and after treatment can be suitably accomplished through treatment system 100.


To further illustrate an exemplary method and system 200, with reference to FIG. 2, imaging of a region of interest 206, such as by imaging a region 222 and displaying images 224 of the region of interest 206 on a display 208, to facilitate localization of the treatment area and surrounding structures can initially be conducted. Next, delivery of ultrasound energy 220 at a suitably depth, distribution, timing, and energy level to achieve the desired therapeutic effect of thermal injury or ablation to treat SMAS region 216 can be suitably provided by probe 204 through control by control system 202. Monitoring of the treatment area and surrounding structures before, during, and after therapy, i.e., before, during, and after the delivery of ultrasound energy to SMAS region 216, can be provided to plan and assess the results and/or provide feedback to control system 202 and a system user.


Ultrasound imaging and providing of images 224 can facilitate safe targeting of the SMAS layer 216. For example, with reference to FIG. 2B, specific targeting for the delivery of energy can be better facilitated to avoid heating vital structures such as the facial nerve (motor nerve) 234, parotid gland (which makes saliva) 236, facial artery 238, and trigeminal nerve (for sensory functions) 232 among other regions. Further, use of imaging with targeted energy delivery to provide a limited and controlled depth of treatment can minimize the chance of damaging deep structures, such as for example, the facial nerve that lies below the parotid, which is typically 10 mm thick.


In accordance with an exemplary embodiment, with reference to FIG. 2C, ultrasound imaging of region 222 of the region of interest 206 can also be used to delineate SMAS layer 216 as the superficial, echo-dense layer overlying facial muscles 218. Such muscles can be seen via imaging region 222 by moving muscles 218, for example by extensional flexing of muscle layer 218 generally towards directions 250 and 252. Such imaging of region 222 may be further enhanced via signal and image processing. Once SMAS layer 216 is localized and/or identified, SMAS layer 216 is ready for treatment.


The delivery of ultrasound energy 220 at a suitably depth, distribution, timing, and energy level is provided by probe 204 through controlled operation by control system 202 to achieve the desired therapeutic effect of thermal injury to treat SMAS region 216. During operation, probe 204 can also be mechanically and/or electronically scanned within tissue surface region 226 to treat an extended area. In addition, spatial control of a treatment depth 220 can be suitably adjusted in various ranges, such as between a wide range of approximately 0 to 15 mm, suitably fixed to a few discrete depths, with an adjustment limited to a fine range, e.g. approximately between 3 mm to 9 mm, and/or dynamically adjusted during treatment, to treat SMAS layer 216 that typically lies at a depth between approximately 5 mm to 7 mm. Before, during, and after the delivery of ultrasound energy to SMAS region 216, monitoring of the treatment area and surrounding structures can be provided to plan and assess the results and/or provide feedback to control system 202 and a system user.


For example, in accordance with an exemplary embodiment, with additional reference to FIG. 2D, ultrasound imaging of region 222 can be used to monitor treatment by watching the amount of shrinkage of SMAS layer 216 in direction of areas 260 and 262, such as in real time or quasi-real time, during and after energy delivery to region 220. The onset of substantially immediate shrinkage of SMAS layer 216 is detectable by ultrasound imaging of region 222 and may be further enhanced via image and signal processing. The monitoring of such shrinkage can be ideal because it can confirm the intended therapeutic goal of noninvasive lifting and tissue tightening; in addition, such monitoring may be used for system feedback. In addition to image monitoring, additional treatment parameters that can be suitably monitored in accordance with various other exemplary embodiments may include temperature, video, profilometry, strain imaging and/or gauges or any other suitable spatial, temporal and/or other tissue parameters.


For example, in accordance with an exemplary embodiment of the present invention, with additional reference to FIG. 2E, an exemplary monitoring method and system 200 may suitably monitor the temperature profile or other tissue parameters of the region of interest 206, such as attenuation or speed of sound of treatment region 222 and suitably adjust the spatial and/or temporal characteristics and energy levels of ultrasound therapy transducer probe 204. The results of such monitoring techniques may be indicated on display 208 in various manners, such as, for example, by way of one-, two-, or three-dimensional images of monitoring results 270, or may comprise an indicator 272, such as a success, fail and/or completed/done type of indication, or combinations thereof.


In accordance with another exemplary embodiment, with reference to FIG. 2F, the targeting of particular region 220 within SMAS layer 216 can be suitably be expanded within region of interest 206 to include a combination of tissues, such as skin 210, dermis 212, fat/adipose tissue 214, SMAS/muscular fascia/and/or other suspensory tissue 216, and muscle 218. Treatment of a combination of such tissues and/or fascia may be treated including at least one of SMAS layer 216 or other layers of muscular fascia in combination with at least one of muscle tissue, adipose tissue, SMAS and/or other muscular fascia, skin, and dermis, can be suitably achieved by treatment system 200. For example, treatment of SMAS layer 216 may be performed in combination with treatment of dermis 280 by suitable adjustment of the spatial and temporal parameters of probe 204 within treatment system 200.


An exemplary control system 202 and display system 208 may be configured in various manners for controlling probe and system functionality. With reference to FIGS. 3A and 3B, in accordance with exemplary embodiments, an exemplary control system 300 can be configured for coordination and control of the entire therapeutic treatment process for noninvasive face lifts and deep tissue tightening. For example, control system 300 can suitably comprise power source components 302, sensing and monitoring components 304, cooling and coupling controls 306, and/or processing and control logic components 308. Control system 300 can be configured and optimized in a variety of ways with more or less subsystems and components to implement the therapeutic system for controlled thermal injury, and the embodiments in FIGS. 3A and 3B are merely for illustration purposes.


For example, for power sourcing components 302, control system 300 can comprise one or more direct current (DC) power supplies 303 configured to provide electrical energy for entire control system 300, including power required by a transducer electronic amplifier/driver 312. A DC current sense device 305 can also be provided to confirm the level of power going into amplifiers/drivers 312 for safety and monitoring purposes.


Amplifiers/drivers 312 can comprise multi-channel or single channel power amplifiers and/or drivers. In accordance with an exemplary embodiment for transducer array configurations, amplifiers/drivers 312 can also be configured with a beamformer to facilitate array focusing. An exemplary beamformer can be electrically excited by an oscillator/digitally controlled waveform synthesizer 310 with related switching logic.


The power sourcing components can also include various filtering configurations 314. For example, switchable harmonic filters and/or matching may be used at the output of amplifier/driver 312 to increase the drive efficiency and effectiveness. Power detection components 316 may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components 316 may be used to monitor the amount of power going to an exemplary probe system.


Various sensing and monitoring components 304 may also be suitably implemented within control system 300. For example, in accordance with an exemplary embodiment, monitoring, sensing and interface control components 324 may be configured to operate with various motion detection systems implemented within transducer probe 204 to receive and process information such as acoustic or other spatial and temporal information from a region of interest. Sensing and monitoring components can also include various controls, interfacing and switches 309 and/or power detectors 316. Such sensing and monitoring components 304 can facilitate open-loop and/or closed-loop feedback systems within treatment system 200.


Cooling/coupling control systems 306 may be provided to remove waste heat from an exemplary probe 204, provide a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from transducer probe 204 to region-of-interest 206. Such cooling/coupling control systems 306 can also be configured to operate in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.


Processing and control logic components 308 can comprise various system processors and digital control logic 307, such as one or more of microcontrollers, microprocessors, field-programmable gate arrays (FPGAs), computer boards, and associated components, including firmware and control software 326, which interfaces to user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. System software and firmware 326 controls all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches 308 can also be suitably configured to control operation.


An exemplary transducer probe 204 can also be configured in various manners and comprise a number of reusable and/or disposable components and parts in various embodiments to facilitate its operation. For example, transducer probe 204 can be configured within any type of transducer probe housing or arrangement for facilitating the coupling of transducer to a tissue interface, with such housing comprising various shapes, contours and configurations. Transducer probe 204 can comprise any type of matching, such as for example, electric matching, which may be electrically switchable; multiplexer circuits and/or aperture/element selection circuits; and/or probe identification devices, to certify probe handle, electric matching, transducer usage history and calibration, such as one or more serial EEPROM (memories). Transducer probe 204 may also comprise cables and connectors; motion mechanisms, motion sensors and encoders; thermal monitoring sensors; and/or user control and status related switches, and indicators such as LEDs. For example, a motion mechanism in probe 204 may be used to controllably create multiple lesions, or sensing of probe motion itself may be used to controllably create multiple lesions and/or stop creation of lesions, e.g. for safety reasons if probe 204 is suddenly jerked or is dropped. In addition, an external motion encoder arm may be used to hold the probe during use, whereby the spatial position and attitude of probe 104 is sent to the control system to help controllably create lesions. Furthermore, other sensing functionality such as profilometers or other imaging modalities may be integrated into the probe in accordance with various exemplary embodiments. Moreover, the therapy contemplated herein can also be produced, for example, by transducers disclosed in U.S. application Ser. No. 10/944,499, filed on Sep. 16, 2004, entitled Method And System For Ultrasound Treatment With A Multi-Directional Transducer and U.S. application Ser. No. 10/944,500, filed on Sep. 16, 2004, and entitled System And Method For Variable Depth Ultrasound Treatment, both hereby incorporated by reference.


With reference to FIGS. 4A and 4B, in accordance with an exemplary embodiment, a transducer probe 400 can comprise a control interface 402, a transducer 404, coupling components 406, and monitoring/sensing components 408, and/or motion mechanism 410. However, transducer probe 400 can be configured and optimized in a variety of ways with more or less parts and components to provide ultrasound energy for controlled thermal injury, and the embodiment in FIGS. 4A and 4B are merely for illustration purposes.


Control interface 402 is configured for interfacing with control system 300 to facilitate control of transducer probe 400. Control interface components 402 can comprise multiplexer/aperture select 424, switchable electric matching networks 426, serial EEPROMs and/or other processing components and matching and probe usage information 430, cable 428 and interface connectors 432.


Coupling components 406 can comprise various devices to facilitate coupling of transducer probe 400 to a region of interest. For example, coupling components 406 can comprise cooling and acoustic coupling system 420 configured for acoustic coupling of ultrasound energy and signals. Acoustic cooling/coupling system 420 with possible connections such as manifolds may be utilized to couple sound into the region-of-interest, control temperature at the interface and deeper into tissue, provide liquid-filled lens focusing, and/or to remove transducer waste heat. Coupling system 420 may facilitate such coupling through use of various coupling mediums, including air and other gases, water and other fluids, gels, solids, and/or any combination thereof, or any other medium that allows for signals to be transmitted between transducer active elements 412 and a region of interest. In addition to providing a coupling function, in accordance with an exemplary embodiment, coupling system 420 can also be configured for providing temperature control during the treatment application. For example, coupling system 420 can be configured for controlled cooling of an interface surface or region between transducer probe 400 and a region of interest and beyond by suitably controlling the temperature of the coupling medium. The suitable temperature for such coupling medium can be achieved in various manners, and utilize various feedback systems, such as thermocouples, thermistors or any other device or system configured for temperature measurement of a coupling medium. Such controlled cooling can be configured to further facilitate spatial and/or thermal energy control of transducer probe 400.


In accordance with an exemplary embodiment, with additional reference to FIG. 11, acoustic coupling and cooling 1140 can be provided to acoustically couple energy and imaging signals from transducer probe 1104 to and from the region of interest 1106, to provide thermal control at the probe 1100 to region-of-interest interface (skin) 1110 and deeper into tissue, and to remove potential waste heat from the transducer probe at region 1144. Temperature monitoring can be provided at the coupling interface via a thermal sensor 1146 to provides a mechanism of temperature measurement 1148 and control via control system 1102 and a thermal control system 1142. Thermal control may consist of passive cooling such as via heat sinks or natural conduction and convection or via active cooling such as with peltier thermoelectric coolers, refrigerants, or fluid-based systems comprised of pump, fluid reservoir, bubble detection, flow sensor, flow channels/tubing 1144 and thermal control 1142.


With continued reference to FIG. 4, monitoring and sensing components 408 can comprise various motion and/or position sensors 416, temperature monitoring sensors 418, user control and feedback switches 414 and other like components for facilitating control by control system 300, e.g., to facilitate spatial and/or temporal control through open-loop and closed-loop feedback arrangements that monitor various spatial and temporal characteristics.


Motion mechanism 410 can comprise manual operation, mechanical arrangements, or some combination thereof. For example, a motion mechanism driver 322 can be suitably controlled by control system 300, such as through the use of accelerometers, encoders or other position/orientation devices 416 to determine and enable movement and positions of transducer probe 400. Linear, rotational or variable movement can be facilitated, e.g., those depending on the treatment application and tissue contour surface.


Transducer 404 can comprise one or more transducers configured for treating of SMAS layers and targeted regions. Transducer 404 can also comprise one or more transduction elements and/or lenses 412. The transduction elements can comprise a piezoelectrically active material, such as lead zirconante titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. In addition to, or instead of, a piezoelectrically active material, transducer 404 can comprise any other materials configured for generating radiation and/or acoustical energy. Transducer 404 can also comprise one or more matching layers configured along with the transduction element such as coupled to the piezoelectrically active material. Acoustic matching layers and/or damping may be employed as necessary to achieve the desired electroacoustic response.


In accordance with an exemplary embodiment, the thickness of the transduction element of transducer 404 can be configured to be uniform. That is, a transduction element 412 can be configured to have a thickness that is substantially the same throughout. In accordance with another exemplary embodiment, the thickness of a transduction element 412 can also be configured to be variable. For example, transduction element(s) 412 of transducer 404 can be configured to have a first thickness selected to provide a center operating frequency of approximately 2 kHz to 75 MHz, such as for imaging applications. Transduction element 412 can also be configured with a second thickness selected to provide a center operating frequency of approximately 2 to 400 MHz, and typically between 4 MHz and 15 MHz for therapy application. Transducer 404 can be configured as a single broadband transducer excited with at least two or more frequencies to provide an adequate output for generating a desired response. Transducer 404 can also be configured as two or more individual transducers, wherein each transducer comprises one or more transduction element. The thickness of the transduction elements can be configured to provide center-operating frequencies in a desired treatment range.


Transducer 404 may be composed of one or more individual transducers in any combination of focused, planar, or unfocused single-element, multi-element, or array transducers, including 1-D, 2-D, and annular arrays; linear, curvilinear, sector, or spherical arrays; spherically, cylindrically, and/or electronically focused, defocused, and/or lensed sources. For example, with reference to an exemplary embodiment depicted in FIG. 5, transducer 500 can be configured as an acoustic array 502 to facilitate phase focusing. That is, transducer 500 can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays. By the term “operated,” the electronic apertures of transducer 500 may be manipulated, driven, used, and/or configured to produce and/or deliver an energy beam corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams 508, planar beams 504, and/or focused beams 506, each of which may be used in combination to achieve different physiological effects in a region of interest 510. Transducer 500 may additionally comprise any software and/or other hardware for generating, producing and or driving a phased aperture array with one or more electronic time delays.


Transducer 500 can also be configured to provide focused treatment to one or more regions of interest using various frequencies. In order to provide focused treatment, transducer 500 can be configured with one or more variable depth devices to facilitate treatment. For example, transducer 500 may be configured with variable depth devices disclosed in U.S. patent application Ser. No. 10/944,500, entitled “System and Method for Variable Depth Ultrasound”, filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and incorporated herein by reference. In addition, transducer 500 can also be configured to treat one or more additional ROI 510 through the enabling of sub-harmonics or pulse-echo imaging, as disclosed in U.S. patent application Ser. No. 10/944,499, entitled “Method and System for Ultrasound Treatment with a Multi-directional Transducer”, filed on Sep. 16, 2004, having at least one common inventor and a common Assignee as the present application, and also incorporated herein by reference.


Moreover, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and or defocus the sound field. For example, with reference to exemplary embodiments depicted in FIGS. 6A and 6B, transducer 600 may also be configured with an electronic focusing array 602 in combination with one or more transduction elements 606 to facilitate increased flexibility in treating ROI 610. Array 602 may be configured in a manner similar to transducer 502. That is, array 604 can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, T1, T2 . . . Tj. By the term “operated,” the electronic apertures of array 602 may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI 610.


Transduction elements 606 may be configured to be concave, convex, and/or planar. For example, in an exemplary embodiment depicted in FIG. 6A, transduction elements 606 are configured to be concave in order to provide focused energy for treatment of ROI 610. Additional embodiments are disclosed in U.S. patent application Ser. No. 10/944,500, entitled “Variable Depth Transducer System and Method”, and again incorporated herein by reference.


In another exemplary embodiment, depicted in FIG. 6B, transduction elements 606 can be configured to be substantially flat in order to provide substantially uniform energy to ROI 610. While FIGS. 6A and 6B depict exemplary embodiments with transduction elements 604 configured as concave and substantially flat, respectively, transduction elements 604 can be configured to be concave, convex, and/or substantially flat. In addition, transduction elements 604 can be configured to be any combination of concave, convex, and/or substantially flat structures. For example, a first transduction element can be configured to be concave, while a second transduction element can be configured to be substantially flat.


With reference to FIGS. 8A and 8B, transducer 800 can be configured as single-element arrays, wherein a single-element 802, e.g., a transduction element of various structures and materials, can be configured with a plurality of masks 804, such masks comprising ceramic, metal or any other material or structure for masking or altering energy distribution from element 802, creating an array of energy distributions 808. Masks 804 can be coupled directly to element 802 or separated by a standoff 806, such as any suitably solid or liquid material.


An exemplary transducer 404 can also be configured as an annular array to provide planar, focused and/or defocused acoustical energy. For example, with reference to FIGS. 10A and 10B, in accordance with an exemplary embodiment, an annular array 1000 can comprise a plurality of rings 1012, 1014, 1016 to N. Rings 1012, 1014, 1016 to N can be mechanically and electrically isolated into a set of individual elements, and can create planar, focused, or defocused waves. For example, such waves can be centered on-axis, such as by methods of adjusting corresponding transmit and/or receive delays, τ1, τ2, τ3 . . . τN. An electronic focus 1020 can be suitably moved along various depth positions, and can enable variable strength or beam tightness, while an electronic defocus can have varying amounts of defocusing. In accordance with an exemplary embodiment, a lens and/or convex or concave shaped annular array 1000 can also be provided to aid focusing or defocusing such that any time differential delays can be reduced. Movement of annular array 1000 in one, two or three-dimensions, or along any path, such as through use of probes and/or any conventional robotic arm mechanisms, may be implemented to scan and/or treat a volume or any corresponding space within a region of interest.


Transducer 404 can also be configured in other annular or non-array configurations for imaging/therapy functions. For example, with reference to FIGS. 10C-10F, a transducer can comprise an imaging element 1012 configured with therapy element(s) 1014. Elements 1012 and 1014 can comprise a single-transduction element, e.g., a combined imaging/transducer element, or separate elements, can be electrically isolated 1022 within the same transduction element or between separate imaging and therapy elements, and/or can comprise standoff 1024 or other matching layers, or any combination thereof. For example, with particular reference to FIG. 10F, a transducer can comprise an imaging element 1012 having a surface 1028 configured for focusing, defocusing or planar energy distribution, with therapy elements 1014 including a stepped-configuration lens configured for focusing, defocusing, or planar energy distribution.


In accordance with various exemplary embodiments of the present invention, transducer 404 may be configured to provide one, two and/or three-dimensional treatment applications for focusing acoustic energy to one or more regions of interest. For example, as discussed above, transducer 404 can be suitably diced to form a one-dimensional array, e.g., transducer 602 comprising a single array of sub-transduction elements.


In accordance with another exemplary embodiment, transducer 404 may be suitably diced in two-dimensions to form a two-dimensional array. For example, with reference to FIG. 9, an exemplary two-dimensional array 900 can be suitably diced into a plurality of two-dimensional portions 902. Two-dimensional portions 902 can be suitably configured to focus on the treatment region at a certain depth, and thus provide respective slices 904, 907 of the treatment region. As a result, the two-dimensional array 900 can provide a two-dimensional slicing of the image place of a treatment region, thus providing two-dimensional treatment.


In accordance with another exemplary embodiment, transducer 404 may be suitably configured to provide three-dimensional treatment. For example, to provide-three dimensional treatment of a region of interest, with reference again to FIG. 1, a three-dimensional system can comprise a transducer within probe 104 configured with an adaptive algorithm, such as, for example, one utilizing three-dimensional graphic software, contained in a control system, such as control system 102. The adaptive algorithm is suitably configured to receive two-dimensional imaging, temperature and/or treatment or other tissue parameter information relating to the region of interest, process the received information, and then provide corresponding three-dimensional imaging, temperature and/or treatment information.


In accordance with an exemplary embodiment, with reference again to FIG. 9, an exemplary three-dimensional system can comprise a two-dimensional array 900 configured with an adaptive algorithm to suitably receive 904 slices from different image planes of the treatment region, process the received information, and then provide volumetric information 906, e.g., three-dimensional imaging, temperature and/or treatment information. Moreover, after processing the received information with the adaptive algorithm, the two-dimensional array 900 may suitably provide therapeutic heating to the volumetric region 906 as desired.


In accordance with other exemplary embodiments, rather than utilizing an adaptive algorithm, such as three-dimensional software, to provide three-dimensional imaging and/or temperature information, an exemplary three-dimensional system can comprise a single transducer 404 configured within a probe arrangement to operate from various rotational and/or translational positions relative to a target region.


To further illustrate the various structures for transducer 404, with reference to FIG. 7, ultrasound therapy transducer 700 can be configured for a single focus, an array of foci, a locus of foci, a line focus, and/or diffraction patterns. Transducer 700 can also comprise single elements, multiple elements, annular arrays, one-, two-, or three-dimensional arrays, broadband transducers, and/or combinations thereof, with or without lenses, acoustic components, and mechanical and/or electronic focusing. Transducers configured as spherically focused single elements 702, annular arrays 704, annular arrays with damped regions 706, line focused single elements 708, 1-D linear arrays 710, 1-D curvilinear arrays in concave or convex form, with or without elevation focusing 712, 2-D arrays 714, and 3-D spatial arrangements of transducers may be used to perform therapy and/or imaging and acoustic monitoring functions. For any transducer configuration, focusing and/or defocusing may be in one plane or two planes via mechanical focus 720, convex lens 722, concave lens 724, compound or multiple lenses 726, planar form 728, or stepped form, such as illustrated in FIG. 10F. Any transducer or combination of transducers may be utilized for treatment. For example, an annular transducer may be used with an outer portion dedicated to therapy and the inner disk dedicated to broadband imaging wherein such imaging transducer and therapy transducer have different acoustic lenses and design, such as illustrated in FIG. 10C-10F.


Moreover, such transduction elements 700 may comprise a piezoelectrically active material, such as lead zirconante titanate (PZT), or any other piezoelectrically active material, such as a piezoelectric ceramic, crystal, plastic, and/or composite materials, as well as lithium niobate, lead titanate, barium titanate, and/or lead metaniobate. Transduction elements 700 may also comprise one or more matching layers configured along with the piezoelectrically active material. In addition to or instead of piezoelectrically active material, transduction elements 700 can comprise any other materials configured for generating radiation and/or acoustical energy. A means of transferring energy to and from the transducer to the region of interest is provided.


In accordance with another exemplary embodiment, with reference to FIG. 12, an exemplary treatment system 200 can be configured with and/or combined with various auxiliary systems to provide additional functions. For example, an exemplary treatment system 1200 for treating a region of interest 1202 can comprise a control system 1206, a probe 1204, and a display 1208. Treatment system 1200 further comprises an auxiliary imaging subsystem 1272 and/or auxiliary monitoring modality 1274 may be based upon at least one of photography and other visual optical methods, magnetic resonance imaging (MRI), computed tomography (CT), optical coherence tomography (OCT), electromagnetic, microwave, or radio frequency (RF) methods, positron emission tomography (PET), infrared, ultrasound, acoustic, or any other suitable method of visualization, localization, or monitoring of SMAS layers within region-of-interest 1202, including imaging/monitoring enhancements. Such imaging/monitoring enhancement for ultrasound imaging via probe 1204 and control system 1206 could comprise M-mode, persistence, filtering, color, Doppler, and harmonic imaging among others; furthermore an ultrasound treatment system 1270, as a primary source of treatment, may be combined with a secondary treatment subsystem 1276, including radio frequency (RF), intense pulsed light (IPL), laser, infrared laser, microwave, or any other suitable energy source.


In accordance with another exemplary embodiment, with reference to FIG. 13, treatment composed of imaging, monitoring, and/or therapy to a region of interest may be further aided, augmented, and/or delivered with passive or active devices 1304 within the oral cavity. For example, if passive or active device 1304 is a second transducer or acoustic reflector acoustically coupled to the cheek lining it is possible to obtain through transmission, tomographic, or round-trip acoustic waves which are useful for treatment monitoring, such as in measuring acoustic speed of sound and attenuation, which are temperature dependent; furthermore such a transducer could be used to treat and/or image. In addition an active, passive, or active/passive object 1304 may be used to flatten the skin, and/or may be used as an imaging grid, marker, or beacon, to aid determination of position. A passive or active device 1304 may also be used to aid cooling or temperature control. Natural air in the oral cavity may also be used as passive device 1304 whereby it may be utilized to as an acoustic reflector to aid thickness measurement and monitoring function.


The present invention has been described above with reference to various exemplary embodiments. However, those skilled in the art will recognize that changes and modifications may be made to the exemplary embodiments without departing from the scope of the present invention. For example, the various operational steps, as well as the components for carrying out the operational steps, may be implemented in alternate ways depending upon the particular application or in consideration of any number of cost functions associated with the operation of the system, e.g., various of the steps may be deleted, modified, or combined with other steps. These and other changes or modifications are intended to be included within the scope of the present invention, as set forth in the following claims.

Claims
  • 1. A method of treating the skin, the method comprising: positioning an ultrasound probe system on a skin surface, the ultrasound probe system comprising an ultrasound therapy element and a motion mechanism;wherein the motion mechanism is controlled by a control system in communication with the ultrasound probe;using the ultrasound therapy element to treat a region of interest under the skin surface comprising a tissue comprising a portion of at least one of muscular fascia and SMAS tissue;wherein the ultrasound therapy element is coupled to the motion mechanism within the probe;wherein the ultrasound therapy element is configured for targeted delivery of ablative ultrasound energy to form a thermal lesion with at least a temperature sufficient to treat at least a portion of the tissue at a depth of up to 9 mm from the skin surface; andactivating the motion mechanism to move the ultrasound therapy element to form a plurality of the thermal lesions along a line at the depth into the tissue to cause any one of the group consisting of ablation, deactivation, and shrinkage of at least a portion of the tissue.
  • 2. The method according to claim 1, wherein the therapy element is configured to treat with a treatment frequency of between 4 MHz and 15 MHz and wherein the plurality of thermal lesions facilitates a tightening of the tissue that leads to any one of a face lift, a treatment of laxity, and a treatment of sagging in the skin surface.
  • 3. The method according to claim 1, wherein the depth of the lesion is within a range of 0 to 5 mm from the skin surface.
  • 4. The method according to claim 1, wherein the depth of the lesion is within a range of 3 mm to 9 mm from the skin surface.
  • 5. The method according to claim 1, wherein the ultrasound probe system comprises at least one combined transducer comprising an ultrasound imaging element and the ultrasound therapy element.
  • 6. The method according to claim 1, wherein the ultrasound therapy element is a single element transducer.
  • 7. The method according to claim 1, further comprising: using a second ultrasound therapy element to treat the region of interest;wherein the second ultrasound therapy element is coupled to the motion mechanism within the probe;wherein the second ultrasound therapy element is configured for targeted delivery of ablative ultrasound energy to form a thermal lesion with at least a temperature sufficient to treat at least a portion of the tissue at a second depth of up to 9 mm from the skin surface; andactivating the motion mechanism to form a plurality of the thermal lesions along a line at the second depth into the tissue to cause any one of the group consisting of ablation, deactivation, and shrinkage of at least a portion of the tissue.
  • 8. The method according to claim 1, wherein activating the motion mechanism within the ultrasound probe system comprises communication between and at least two of the group consisting of the control system, an accelerometer, an encoder and a position/orientation device.
  • 9. The method according to claim 1, further comprising an imaging element configured to image with an imaging frequency of between 2 kHz to 75 MHz.
  • 10. A method of treating the skin, comprising: using an ultrasound device to emit ultrasound energy from a therapy element housed within an ultrasound probe to a region of interest at a depth under a skin surface in the range of 0.5 mm to 5 mm, the region of interest comprising a portion of at least one of muscular fascia and SMAS tissue, wherein emitting ultrasound energy ablates a portion of the region of interest under the skin surface to facilitate a tightening of the skin surface; andmoving a motion mechanism operably connected to the therapy element within the ultrasound probe for controllably creating a plurality of thermal lesions along a line at the depth in the range of 0.5 mm to 5 mm under the skin surface,wherein the motion mechanism comprises at least one of the group consisting of an accelerometer, encoder and a position/orientation device;wherein the motion mechanism is controlled by a control system in communication with the ultrasound probe.
  • 11. The method of claim 10, further comprising imaging of the region of interest with an ultrasound imaging element housed within the ultrasound probe, the imaging element configured to image with an imaging frequency of between 2 kHz to 75 MHz.
  • 12. The method of claim 11, wherein using the ultrasound device comprises the adjustment of spatial and temporal parameters based on the imaging, wherein the imaging monitors shrinkage of the region of interest during or after emitting the ultrasound energy.
  • 13. The method of claim 10, wherein the emitting ultrasound energy further comprises ablating adipose tissue.
  • 14. The method according to claim 10, further comprising: emitting ultrasound energy from a second therapy element to treat the region of interest;wherein the second therapy element is coupled to the motion mechanism within the ultrasound probe;wherein the second therapy element is configured for targeted delivery of ablative ultrasound energy to form a second thermal lesion with at least a temperature sufficient to treat at least a portion of the tissue at a second depth of 0.5 mm to 5 mm from the skin surface; andactivating the motion mechanism to move the second therapy element within the probe to form a plurality of the second thermal lesions along a line at the second depth into the tissue to cause any one of the group consisting of ablation, deactivation, and shrinkage of at least a portion of the tissue.
  • 15. A method for treating the skin, comprising: focusing therapeutic ultrasound energy from a therapy element to a treatment region comprising a portion of at least one of SMAS tissue and muscular fascia at a depth in the range of up to 9 mm below the skin surface,wherein the therapeutic ultrasound energy ablates a portion of the treatment region to facilitate tissue tightening at the treatment region,wherein the therapy element is housed within an ultrasound probe; andmoving a motion mechanism operably connected to the therapy element within the ultrasound probe for controllably creating a plurality of thermal lesions along a line at the depth at the treatment region,wherein the motion mechanism is controlled by a control system in communication with the ultrasound probe, wherein the control system controls at least one of a spatial parameter and a temporal parameter.
  • 16. The method of claim 15, further comprising imaging of the region of interest with an ultrasound imaging element housed within the ultrasound probe, the imaging element configured to image with an imaging frequency of between 2 kHz to 75 MHz.
  • 17. The method of claim 15, wherein the focusing therapeutic ultrasound energy further comprises ablating adipose tissue.
  • 18. The method of claim 16, further comprising displaying at least one thermal lesion at the depth on a display electrically connected to the ultrasound imaging element.
  • 19. The method of claim 15, wherein the therapy element is a single element transducer.
  • 20. The method according to claim 15, further comprising: focusing therapeutic ultrasound energy from a second therapy element to treat the treatment region;wherein the second therapy element is coupled to the motion mechanism within the ultrasound probe;wherein the second therapy element is configured for targeted delivery of ablative ultrasound energy to form a second thermal lesion with at least a temperature sufficient to treat a second portion of the treatment region at a second depth of up to 9 mm below the skin surface; andmoving the motion mechanism to move the second therapy element within the ultrasound probe to form a plurality of the second thermal lesions along a second line at the second depth into the tissue to cause any one of the group consisting of ablation, deactivation, and shrinkage of at least a portion of the treatment region.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 13/444,336, now U.S. Pat. No. 8,366,622, titled “Treatment Of Sub-Dermal Regions For Cosmetic Effects” filed on Apr. 11, 2012, which is a continuation of U.S. application Ser. No. 11/163,151 titled “Method And System For Noninvasive Face Lifts And Deep Tissue Tightening” filed on Oct. 6, 2005, now abandoned, which claims the benefit of priority to U.S. Provisional Application No. 60/616,755, titled “Method And System For Noninvasive Face Lifts And Deep Tissue Tightening” filed on Oct. 6, 2004, each of which is incorporated in its entirety by reference herein.

US Referenced Citations (541)
Number Name Date Kind
2427348 Bond et al. Sep 1947 A
3913386 Saglio Oct 1975 A
3965455 Hurwitz Jun 1976 A
3992925 Perilhou Nov 1976 A
4039312 Patru Aug 1977 A
4059098 Murdock Nov 1977 A
4101795 Fukumoto Jul 1978 A
4213344 Rose Jul 1980 A
4276491 Daniel Jun 1981 A
4315514 Drewes et al. Feb 1982 A
4325381 Glenn Apr 1982 A
4343301 Indech Aug 1982 A
4372296 Fahim Feb 1983 A
4381007 Doss Apr 1983 A
4381787 Hottinger May 1983 A
4397314 Vaguine Aug 1983 A
4409839 Taenzer Oct 1983 A
4441486 Pounds Apr 1984 A
4452084 Taenzer Jun 1984 A
4484569 Driller Nov 1984 A
4513749 Kino Apr 1985 A
4527550 Ruggera et al. Jul 1985 A
4528979 Marchenko Jul 1985 A
4567895 Putzke Feb 1986 A
4586512 Do-Huu May 1986 A
4601296 Yerushalmi Jul 1986 A
4646756 Watmough Mar 1987 A
4663358 Hyon May 1987 A
4668516 Duraffourd et al. May 1987 A
4697588 Reichenberger Oct 1987 A
4757820 Itoh Jul 1988 A
4807633 Fry Feb 1989 A
4858613 Fry Aug 1989 A
4860732 Hasegawa et al. Aug 1989 A
4865041 Hassler Sep 1989 A
4865042 Umemura Sep 1989 A
4867169 Machida Sep 1989 A
4874562 Hyon Oct 1989 A
4875487 Seppi Oct 1989 A
4893624 Lele Jan 1990 A
4896673 Rose Jan 1990 A
D306965 Jaworski Apr 1990 S
4917096 Englehart Apr 1990 A
4938216 Lele Jul 1990 A
4938217 Lele Jul 1990 A
4947046 Kawabata et al. Aug 1990 A
4951653 Fry Aug 1990 A
4955365 Fry Sep 1990 A
4958626 Nambu Sep 1990 A
4976709 Sand Dec 1990 A
4979501 Valchanov Dec 1990 A
5012797 Liang May 1991 A
5036855 Fry Aug 1991 A
5054310 Flynn Oct 1991 A
5054470 Fry Oct 1991 A
5115814 Griffith May 1992 A
5117832 Sanghvi Jun 1992 A
5123418 Saurel Jun 1992 A
5143063 Fellner Sep 1992 A
5143074 Dory Sep 1992 A
5150711 Dory Sep 1992 A
5150714 Green Sep 1992 A
5156144 Iwasaki Oct 1992 A
5158536 Sekins Oct 1992 A
5163421 Bernstein Nov 1992 A
5191880 McLeod Mar 1993 A
5209720 Unger May 1993 A
5224467 Oku Jul 1993 A
5230334 Klopotek Jul 1993 A
5230338 Allen et al. Jul 1993 A
5265614 Hayakawa Nov 1993 A
5267985 Shimada Dec 1993 A
5269297 Weng Dec 1993 A
5282797 Chess Feb 1994 A
5295484 Marcus Mar 1994 A
5304169 Sand Apr 1994 A
5321520 Inga et al. Jun 1994 A
5360268 Hayashi Nov 1994 A
5370121 Reichenberger Dec 1994 A
5371483 Bhardwaj Dec 1994 A
5380280 Peterson Jan 1995 A
5391140 Schaetzle et al. Feb 1995 A
5406503 Williams Apr 1995 A
5419327 Rohwedder May 1995 A
5435311 Umemura Jul 1995 A
5458596 Lax Oct 1995 A
5460595 Hall et al. Oct 1995 A
5471988 Fujio Dec 1995 A
5487388 Rello et al. Jan 1996 A
5492126 Hennige Feb 1996 A
5496256 Bock Mar 1996 A
5501655 Rolt Mar 1996 A
5503320 Webster et al. Apr 1996 A
5507790 Weiss Apr 1996 A
5520188 Hennige May 1996 A
5522869 Burdette Jun 1996 A
5523058 Umemura et al. Jun 1996 A
5524620 Rosenschein Jun 1996 A
5524624 Tepper Jun 1996 A
5524625 Okazaki Jun 1996 A
5526624 Berg Jun 1996 A
5526812 Dumoulin et al. Jun 1996 A
5526814 Cline et al. Jun 1996 A
5526815 Granz Jun 1996 A
5540235 Wilson Jul 1996 A
5558092 Unger Sep 1996 A
5560362 Sliwa et al. Oct 1996 A
5575291 Hayakawa Nov 1996 A
5575807 Faller Nov 1996 A
5577502 Darrow et al. Nov 1996 A
5577991 Akui et al. Nov 1996 A
5580575 Unger et al. Dec 1996 A
5601526 Chapelon Feb 1997 A
5603323 Pflugrath et al. Feb 1997 A
5609562 Kaali Mar 1997 A
5615091 Palatnik Mar 1997 A
5617858 Taverna et al. Apr 1997 A
5618275 Bock Apr 1997 A
5620479 Diederich Apr 1997 A
5638819 Manwaring et al. Jun 1997 A
5647373 Paltieli Jul 1997 A
5655538 Lorraine Aug 1997 A
5657760 Ying Aug 1997 A
5658328 Johnson Aug 1997 A
5660836 Knowlton Aug 1997 A
5665053 Jacobs Sep 1997 A
5676692 Sanghvi Oct 1997 A
5685820 Riek et al. Nov 1997 A
5690608 Watanabe Nov 1997 A
5694936 Fujimoto Dec 1997 A
5697897 Buchholtz Dec 1997 A
5701900 Shehada et al. Dec 1997 A
5715823 Wood et al. Feb 1998 A
5720287 Chapelon et al. Feb 1998 A
5722411 Suzuki Mar 1998 A
5727554 Kalend et al. Mar 1998 A
5735280 Sherman et al. Apr 1998 A
5743863 Chapelon Apr 1998 A
5746005 Steinberg May 1998 A
5746762 Bass May 1998 A
5748767 Raab May 1998 A
5749364 Sliwa et al. May 1998 A
5755228 Wilson et al. May 1998 A
5755753 Knowlton May 1998 A
5762066 Law Jun 1998 A
5769790 Watkins Jun 1998 A
5795297 Daigle Aug 1998 A
5795311 Wess Aug 1998 A
5810888 Fenn Sep 1998 A
5817013 Ginn et al. Oct 1998 A
5817021 Reichenberger Oct 1998 A
5820564 Slayton Oct 1998 A
5823962 Schaetzle Oct 1998 A
5827204 Grandia et al. Oct 1998 A
5839751 Lutz Nov 1998 A
5840032 Hatfield et al. Nov 1998 A
5844140 Seale Dec 1998 A
5853367 Chalek et al. Dec 1998 A
5869751 Bonin Feb 1999 A
5871524 Knowlton Feb 1999 A
5873902 Sanghvi Feb 1999 A
5879303 Averkiou et al. Mar 1999 A
5882557 Hayakawa Mar 1999 A
5891034 Bucholz Apr 1999 A
5904659 Duarte May 1999 A
5919219 Knowlton Jul 1999 A
5924989 Polz Jul 1999 A
5928169 Schatzle et al. Jul 1999 A
5931805 Brisken Aug 1999 A
5938606 Bonnefous Aug 1999 A
5938612 Kline-Schoder Aug 1999 A
5948011 Knowlton Sep 1999 A
5957844 Dekel Sep 1999 A
5957882 Nita et al. Sep 1999 A
5967980 Ferre et al. Oct 1999 A
5968034 Fullmer Oct 1999 A
5971949 Levin Oct 1999 A
5984882 Rosenchein Nov 1999 A
5997471 Gumb et al. Dec 1999 A
5997497 Nita et al. Dec 1999 A
6004262 Putz et al. Dec 1999 A
6007499 Martin et al. Dec 1999 A
6036646 Barthe Mar 2000 A
6039048 Silberg Mar 2000 A
6042556 Beach Mar 2000 A
6049159 Barthe Apr 2000 A
6050943 Slayton Apr 2000 A
6059727 Fowlkes May 2000 A
6071239 Cribbs Jun 2000 A
6080108 Dunham Jun 2000 A
6086535 Ishibashi Jul 2000 A
6086580 Mordon et al. Jul 2000 A
6090054 Tagishi Jul 2000 A
6093883 Sanghvi Jul 2000 A
6101407 Groezinger Aug 2000 A
6106469 Suzuki et al. Aug 2000 A
6113558 Rosenchein Sep 2000 A
6113559 Klopotek Sep 2000 A
6120452 Barthe Sep 2000 A
6135971 Hutchinson Oct 2000 A
6139499 Wilk Oct 2000 A
6159150 Yale et al. Dec 2000 A
6171244 Finger et al. Jan 2001 B1
6176840 Nishimura Jan 2001 B1
6183426 Akisada Feb 2001 B1
6183502 Takeuchi Feb 2001 B1
6183773 Anderson Feb 2001 B1
6190323 Dias Feb 2001 B1
6190336 Duarte Feb 2001 B1
6193658 Wendelken Feb 2001 B1
6210327 Brackett et al. Apr 2001 B1
6213948 Barthe Apr 2001 B1
6216029 Paltieli Apr 2001 B1
6233476 Strommer et al. May 2001 B1
6234990 Rowe et al. May 2001 B1
6241753 Knowlton Jun 2001 B1
6246898 Vesely et al. Jun 2001 B1
6251088 Kaufman et al. Jun 2001 B1
6268405 Yao Jul 2001 B1
6273864 Duarte Aug 2001 B1
6287257 Matichuk Sep 2001 B1
6296619 Brisken Oct 2001 B1
6301989 Brown et al. Oct 2001 B1
6311090 Knowlton Oct 2001 B1
6315741 Martin Nov 2001 B1
6322509 Pan et al. Nov 2001 B1
6322532 D'Sa Nov 2001 B1
6325540 Lounsberry et al. Dec 2001 B1
6325769 Klopotek Dec 2001 B1
6325798 Edwards et al. Dec 2001 B1
6350276 Knowlton Feb 2002 B1
6356780 Licato et al. Mar 2002 B1
6361531 Hissong Mar 2002 B1
6375672 Aksan Apr 2002 B1
6377854 Knowlton Apr 2002 B1
6377855 Knowlton Apr 2002 B1
6381497 Knowlton Apr 2002 B1
6381498 Knowlton Apr 2002 B1
6387380 Knowlton May 2002 B1
6390982 Bova et al. May 2002 B1
6405090 Knowlton Jun 2002 B1
6409720 Hissong Jun 2002 B1
6413253 Koop Jul 2002 B1
6413254 Hissong Jul 2002 B1
6419648 Vitek Jul 2002 B1
6425865 Salcudean Jul 2002 B1
6425867 Vaezy Jul 2002 B1
6425912 Knowlton Jul 2002 B1
6428477 Mason Aug 2002 B1
6428532 Doukas Aug 2002 B1
6430446 Knowlton Aug 2002 B1
6432067 Martin Aug 2002 B1
6432101 Weber Aug 2002 B1
6436061 Costantino Aug 2002 B1
6438424 Knowlton Aug 2002 B1
6440071 Slayton Aug 2002 B1
6440121 Weber Aug 2002 B1
6443914 Constantino Sep 2002 B1
6453202 Knowlton Sep 2002 B1
6461378 Knowlton Oct 2002 B1
6470216 Knowlton Oct 2002 B1
6491657 Rowe Dec 2002 B2
6500121 Slayton Dec 2002 B1
6500141 Irion Dec 2002 B1
6508774 Acker Jan 2003 B1
6511428 Azuma Jan 2003 B1
6514244 Pope Feb 2003 B2
6524250 Weber Feb 2003 B1
6540679 Slayton Apr 2003 B2
6540685 Rhoads et al. Apr 2003 B1
6554771 Buil et al. Apr 2003 B1
6569099 Babaev May 2003 B1
6595934 Hissong Jul 2003 B1
6599256 Acker Jul 2003 B1
6607498 Eshel Aug 2003 B2
6623430 Slayton Sep 2003 B1
6626854 Friedman Sep 2003 B2
6626855 Weng Sep 2003 B1
6638226 He et al. Oct 2003 B2
6645162 Friedman Nov 2003 B2
6662054 Kreindel Dec 2003 B2
6663627 Francischelli Dec 2003 B2
6665806 Shimizu Dec 2003 B1
6666835 Martin Dec 2003 B2
6669638 Miller Dec 2003 B1
6685640 Fry Feb 2004 B1
6692450 Coleman Feb 2004 B1
6699237 Weber Mar 2004 B2
6719449 Laugharn, Jr. et al. Apr 2004 B1
6719694 Weng Apr 2004 B2
6749624 Knowlton Jun 2004 B2
6775404 Pagoulatos et al. Aug 2004 B1
6824516 Batten et al. Nov 2004 B2
6835940 Morikawa et al. Dec 2004 B2
6875176 Mourad Apr 2005 B2
6887239 Elstrom May 2005 B2
6889089 Behl May 2005 B2
6896657 Willis May 2005 B2
6902536 Manna Jun 2005 B2
6905466 Salgo Jun 2005 B2
6918907 Kelly Jul 2005 B2
6920883 Bessette Jul 2005 B2
6921371 Wilson Jul 2005 B2
6932771 Whitmore Aug 2005 B2
6936044 McDaniel Aug 2005 B2
6936046 Hissong Aug 2005 B2
6948843 Laugharn et al. Sep 2005 B2
6953941 Nakano et al. Oct 2005 B2
6958043 Hissong Oct 2005 B2
6974417 Lockwood Dec 2005 B2
6976492 Ingle Dec 2005 B2
6992305 Maezawa et al. Jan 2006 B2
6997923 Anderson Feb 2006 B2
7006874 Knowlton Feb 2006 B2
7020528 Neev Mar 2006 B2
7022089 Ooba Apr 2006 B2
7058440 Heuscher et al. Jun 2006 B2
7063666 Weng Jun 2006 B2
7070565 Vaezy et al. Jul 2006 B2
7074218 Washington et al. Jul 2006 B2
7094252 Koop Aug 2006 B2
7115123 Knowlton Oct 2006 B2
7142905 Slayton Nov 2006 B2
7179238 Hissong Feb 2007 B2
7189230 Knowlton Mar 2007 B2
7229411 Slayton Jun 2007 B2
7235592 Muratoglu Jun 2007 B2
7258674 Cribbs Aug 2007 B2
7273459 Desilets Sep 2007 B2
7297117 Trucco Nov 2007 B2
7347855 Eshel Mar 2008 B2
RE40403 Cho et al. Jun 2008 E
7393325 Barthe Jul 2008 B2
7491171 Barthe et al. Feb 2009 B2
7510536 Foley et al. Mar 2009 B2
7530356 Slayton May 2009 B2
7530958 Slayton May 2009 B2
7571336 Barthe Aug 2009 B2
7601120 Moilanen et al. Oct 2009 B2
7615015 Coleman Nov 2009 B2
7615016 Barthe Nov 2009 B2
7758524 Barthe Jul 2010 B2
7824348 Barthe Nov 2010 B2
7955281 Pedersen et al. Jun 2011 B2
8057389 Barthe et al. Nov 2011 B2
8057465 Sliwa, Jr. et al. Nov 2011 B2
8128618 Gliklich et al. Mar 2012 B2
8133191 Rosenberg et al. Mar 2012 B2
8197409 Foley et al. Jun 2012 B2
8206299 Foley et al. Jun 2012 B2
8211017 Foley et al. Jul 2012 B2
8262591 Pedersen et al. Sep 2012 B2
8273037 Kreindel et al. Sep 2012 B2
8282554 Makin et al. Oct 2012 B2
8333700 Barthe et al. Dec 2012 B1
8366622 Slayton et al. Feb 2013 B2
20010009997 Pope Jul 2001 A1
20010014780 Martin Aug 2001 A1
20010014819 Ingle Aug 2001 A1
20010031922 Weng Oct 2001 A1
20010039380 Larson et al. Nov 2001 A1
20010041880 Brisken Nov 2001 A1
20020000763 Jones Jan 2002 A1
20020040199 Klopotek Apr 2002 A1
20020040442 Ishidera Apr 2002 A1
20020055702 Atala May 2002 A1
20020062077 Emmenegger May 2002 A1
20020062142 Knowlton May 2002 A1
20020082528 Friedman Jun 2002 A1
20020082589 Friedman Jun 2002 A1
20020095143 Key Jul 2002 A1
20020128648 Weber Sep 2002 A1
20020156400 Babaev Oct 2002 A1
20020161357 Anderson Oct 2002 A1
20020165529 Danek Nov 2002 A1
20020168049 Schriever Nov 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020169442 Neev Nov 2002 A1
20020173721 Grunwald et al. Nov 2002 A1
20020193831 Smith Dec 2002 A1
20030014039 Barzell et al. Jan 2003 A1
20030018255 Martin Jan 2003 A1
20030028113 Gilbert et al. Feb 2003 A1
20030032900 Ella Feb 2003 A1
20030036706 Slayton Feb 2003 A1
20030040739 Koop Feb 2003 A1
20030050678 Sierra Mar 2003 A1
20030060736 Martin et al. Mar 2003 A1
20030065313 Koop Apr 2003 A1
20030074023 Kaplan Apr 2003 A1
20030083536 Eshel May 2003 A1
20030097071 Halmann et al. May 2003 A1
20030125629 Ustuner Jul 2003 A1
20030171678 Batten et al. Sep 2003 A1
20030171701 Babaev Sep 2003 A1
20030176790 Slayton Sep 2003 A1
20030191396 Sanghvi Oct 2003 A1
20030200481 Stanley Oct 2003 A1
20030212129 Liu et al. Nov 2003 A1
20030212351 Hissong Nov 2003 A1
20030212393 Knowlton Nov 2003 A1
20030216795 Harth Nov 2003 A1
20030220536 Hissong Nov 2003 A1
20030220585 Hissong Nov 2003 A1
20030236487 Knowlton Dec 2003 A1
20040000316 Knowlton Jan 2004 A1
20040001809 Brisken Jan 2004 A1
20040002705 Knowlton Jan 2004 A1
20040010222 Nunomura et al. Jan 2004 A1
20040015106 Coleman Jan 2004 A1
20040030227 Littrup Feb 2004 A1
20040039312 Hillstead Feb 2004 A1
20040039418 Elstrom Feb 2004 A1
20040059266 Fry Mar 2004 A1
20040073079 Altshuler et al. Apr 2004 A1
20040073113 Salgo Apr 2004 A1
20040073116 Smith Apr 2004 A1
20040077977 Ella et al. Apr 2004 A1
20040082857 Schonenberger Apr 2004 A1
20040082859 Schaer Apr 2004 A1
20040102697 Evron May 2004 A1
20040122493 Ishibashi et al. Jun 2004 A1
20040143297 Ramsey Jul 2004 A1
20040152982 Hwang et al. Aug 2004 A1
20040186535 Knowlton Sep 2004 A1
20040206365 Knowlton Oct 2004 A1
20040210214 Knowlton Oct 2004 A1
20040217675 Desilets Nov 2004 A1
20040249318 Tanaka Dec 2004 A1
20040267252 Washington Dec 2004 A1
20050033201 Takahashi Feb 2005 A1
20050055073 Weber Mar 2005 A1
20050070961 Maki Mar 2005 A1
20050074407 Smith Apr 2005 A1
20050080469 Larson Apr 2005 A1
20050113689 Gritzky May 2005 A1
20050137656 Malak Jun 2005 A1
20050143677 Young et al. Jun 2005 A1
20050154313 Desilets Jul 2005 A1
20050154314 Quistgaard Jul 2005 A1
20050154332 Zanelli Jul 2005 A1
20050154431 Quistgaard Jul 2005 A1
20050187495 Quistgaard Aug 2005 A1
20050191252 Mitsui Sep 2005 A1
20050193451 Quistgaard Sep 2005 A1
20050228281 Nefos Oct 2005 A1
20050240170 Zhang et al. Oct 2005 A1
20050256406 Barthe Nov 2005 A1
20050261584 Eshel Nov 2005 A1
20050267454 Hissong Dec 2005 A1
20060004306 Altshuler Jan 2006 A1
20060020260 Dover et al. Jan 2006 A1
20060025756 Francischelli Feb 2006 A1
20060042201 Curry Mar 2006 A1
20060058664 Barthe Mar 2006 A1
20060058707 Barthe Mar 2006 A1
20060058712 Altshuler et al. Mar 2006 A1
20060074309 Bonnefous Apr 2006 A1
20060074313 Slayton Apr 2006 A1
20060074314 Slayton Apr 2006 A1
20060074355 Slayton Apr 2006 A1
20060079816 Barthe Apr 2006 A1
20060079868 Makin Apr 2006 A1
20060084891 Barthe Apr 2006 A1
20060089632 Barthe Apr 2006 A1
20060089688 Panescu Apr 2006 A1
20060094988 Tosaya May 2006 A1
20060111744 Makin May 2006 A1
20060116671 Slayton Jun 2006 A1
20060122508 Slayton Jun 2006 A1
20060122509 Desilets Jun 2006 A1
20060161062 Arditi et al. Jul 2006 A1
20060184069 Vaitekunas Aug 2006 A1
20060184071 Klopotek Aug 2006 A1
20060206105 Chopra Sep 2006 A1
20060229514 Wiener Oct 2006 A1
20060241440 Eshel Oct 2006 A1
20060241442 Barthe Oct 2006 A1
20060250046 Koizumi et al. Nov 2006 A1
20060261584 Blackburn Nov 2006 A1
20060282691 Barthe Dec 2006 A1
20060291710 Wang et al. Dec 2006 A1
20070032784 Gliklich Feb 2007 A1
20070035201 Desilets Feb 2007 A1
20070055154 Torbati Mar 2007 A1
20070055156 Desilets Mar 2007 A1
20070087060 Dietrich Apr 2007 A1
20070088346 Mirizzi et al. Apr 2007 A1
20070167709 Slayton Jul 2007 A1
20070208253 Slayton Sep 2007 A1
20070239075 Rosenberg Oct 2007 A1
20080027328 Klopotek Jan 2008 A1
20080071255 Barthe Mar 2008 A1
20080086054 Slayton Apr 2008 A1
20080097253 Pedersen et al. Apr 2008 A1
20080167556 Thompson Jul 2008 A1
20080200813 Quistgaard Aug 2008 A1
20080214966 Slayton Sep 2008 A1
20080221491 Slayton Sep 2008 A1
20080275342 Barthe Nov 2008 A1
20080281237 Slayton Nov 2008 A1
20080281255 Slayton Nov 2008 A1
20080294073 Barthe Nov 2008 A1
20080319356 Cain Dec 2008 A1
20090069677 Chen et al. Mar 2009 A1
20090182231 Barthe et al. Jul 2009 A1
20090216159 Slayton et al. Aug 2009 A1
20090226424 Hsu Sep 2009 A1
20090253988 Slayton et al. Oct 2009 A1
20090318909 Debenedictis et al. Dec 2009 A1
20100011236 Barthe et al. Jan 2010 A1
20100022922 Barthe et al. Jan 2010 A1
20100160782 Slayton et al. Jun 2010 A1
20100241035 Barthe et al. Sep 2010 A1
20100280420 Barthe et al. Nov 2010 A1
20110112405 Barthe et al. May 2011 A1
20110178444 Slayton et al. Jul 2011 A1
20120016239 Barthe et al. Jan 2012 A1
20120029353 Slayton et al. Feb 2012 A1
20120035475 Barthe et al. Feb 2012 A1
20120035476 Barthe et al. Feb 2012 A1
20120046547 Barthe et al. Feb 2012 A1
20120053458 Barthe et al. Mar 2012 A1
20120111339 Barthe et al. May 2012 A1
20120143056 Slayton et al. Jun 2012 A1
20120165668 Slayton et al. Jun 2012 A1
20120165848 Slayton et al. Jun 2012 A1
20120197120 Makin et al. Aug 2012 A1
20120197121 Slayton et al. Aug 2012 A1
20120215105 Slayton et al. Aug 2012 A1
20120271294 Barthe et al. Oct 2012 A1
20120330197 Makin et al. Dec 2012 A1
20120330222 Makin et al. Dec 2012 A1
20120330223 Makin et al. Dec 2012 A1
20130012755 Slayton Jan 2013 A1
20130012816 Slayton et al. Jan 2013 A1
20130012838 Jaeger et al. Jan 2013 A1
20130018286 Slayton et al. Jan 2013 A1
20130046209 Slayton et al. Feb 2013 A1
20130066208 Barthe et al. Mar 2013 A1
20130072826 Slayton et al. Mar 2013 A1
Foreign Referenced Citations (79)
Number Date Country
4029175 Mar 1992 DE
10140064 Mar 2003 DE
10219217 Nov 2003 DE
10219297 Nov 2003 DE
20314479 Mar 2004 DE
0344773 Dec 1989 EP
1479412 Nov 1991 EP
0473553 Apr 1992 EP
0661029 Jul 1995 EP
1050322 Nov 2000 EP
1234566 Aug 2002 EP
1262160 Dec 2002 EP
2113099 Aug 1983 GB
63036171 Feb 1988 JP
03048299 Mar 1991 JP
3123559 May 1991 JP
03136642 Jun 1991 JP
4089058 Mar 1992 JP
4-150847 May 1992 JP
7080087 Mar 1995 JP
07505793 Jun 1995 JP
7222782 Aug 1995 JP
11-505440 May 1999 JP
11-506636 Jun 1999 JP
2000166940 Jun 2000 JP
2001170068 Jun 2001 JP
2002078764 Mar 2002 JP
2002515786 May 2002 JP
2002521118 Jul 2002 JP
2002-537939 Nov 2002 JP
2003050298 Feb 2003 JP
2003204982 Jul 2003 JP
2004-147719 May 2004 JP
2005503388 Feb 2005 JP
2005527336 Sep 2005 JP
2005323213 Nov 2005 JP
2006520247 Sep 2006 JP
2009518126 May 2009 JP
2010517695 May 2010 JP
1020010024871 Mar 2001 KR
1020060113930 Nov 2006 KR
1020070065332 Jun 2007 KR
1020070070161 Jul 2007 KR
1020070098856 Oct 2007 KR
1020070104878 Oct 2007 KR
1020070114105 Nov 2007 KR
WO 9625888 Aug 1996 WO
WO 9735518 Oct 1997 WO
WO 9832379 Jul 1998 WO
WO 9933520 Jul 1999 WO
WO 9949788 Oct 1999 WO
WO 0006032 Feb 2000 WO
WO 0015300 Mar 2000 WO
WO 0021612 Apr 2000 WO
WO 0053113 Sep 2000 WO
WO 0128623 Apr 2001 WO
WO 0182777 Nov 2001 WO
WO 0182778 Nov 2001 WO
WO 0187161 Nov 2001 WO
WO 0209813 Feb 2002 WO
WO 0224050 Mar 2002 WO
WO 02092168 Nov 2002 WO
WO 03065347 Aug 2003 WO
WO 03070105 Aug 2003 WO
WO 03077833 Sep 2003 WO
WO 03086215 Oct 2003 WO
WO 03096883 Nov 2003 WO
WO 03099177 Dec 2003 WO
WO 03101530 Dec 2003 WO
WO 2004080147 Sep 2004 WO
WO 2004110558 Dec 2004 WO
WO 2005065408 Jul 2005 WO
WO 2005090978 Sep 2005 WO
WO 2006036870 Apr 2006 WO
WO 2006042168 Apr 2006 WO
WO 2006042201 Apr 2006 WO
WO 2006065671 Jun 2006 WO
WO 2006082573 Aug 2006 WO
WO2009013729 Jan 2009 WO
Non-Patent Literature Citations (44)
Entry
Alster, Tinas S., Tanzi, Elizabeth L., “Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85.
Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600.
Barthe et al., “Ultrasound therapy system and abiation results utilizing miniature imaging/therapy arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3.
Chen, L. et al., “Effect of Blood Perfusion on the ablation of liver perenchyma with high intensity focused ultrasound,” Phys. Med. Biol; 38:1661-1673; 1993b.
Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectometry” Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 27, 2005, pp. 9463-9468.
Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444, 456.
Damianou et al., “Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery,” 1993 IEEE Ultrasound Symposium, pp. 1199-1202.
Daum et al., Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery, IEEE Transactions on Ultrasonics, Feroelectronics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438.
Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 Ultrasonics Symposium, pp. 921-924.
Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” J. Neurosurg., 11:471-478; 1954.
Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9, No. 1.
Harr, G.R. et al., “Tissue Destruction with Focused Ultrasound in Vivo,” Eur. Urol. 23 (suppl. 1):8-11; 1993.
Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” advanced in Polymer Science, 2000, pp. 37-65, vol. 153.
Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7.
Husseini et al, “The Role of Cavitation in Acoustically Activated Drug Delivery,” J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2).
Husseini et al. “Investigating the mechanism of accoustically activated uptake of drugs from Pluronic micelles,” BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6.
Jeffers et al., “Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms,” 1993 IEEE Ultrasonics Symposium, pp. 925-928.
Jenne, J., et al., “Temperature Mapping for High Energy US-Therapy”, 1994 Ultrasonics Symposium, pp. 1879-1882.
Johnson, S.A., et al., “Non-Instrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic Temperature Tomography”, Ultrasonics Symposium Proceedings, pp. 977-982. (1977).
Madersbacher, S. et al., “Tissue Ablation in Bening Prostatic Hyperplasia with High Intensity Focused Ultrasound,” Dur. Urol., 23 (suppl. 1):39-43; 1993.
Makin et al, “B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3.
Makin et al, “Confirmed Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays,” 4th International Symposium on Theraputic Ultrasound, Sep. 19, 2004.
Makin et al., “Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging,” UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11).
Manohar et al, “Photoaccoustic mammography laboratory prototype: imaging of breast tissue phantoms,” Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6.
Mast et al, “Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling nad Experiments,” J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4).
Mitragotri, S., “Healing sound: the use of ultrasound in drug delivery and other therapeutic applications,” Nature Reviews; Drug Delivery, pp. 255-260, vol. 4 (Mar. 2005).
Paradossi et al., “Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications,” Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14.
Reid, Gavin, et al., “Tandem Mass spectometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions,” Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583.
Righetti et al, “Elastographic Characterization of HIFU-Induced Lesions in Canine Livers,” 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113.
Saad et al., “Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors,” Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992).
Sanghvi, N.T., et al., “Transrectal Ablation of Prostrate Tissue Using Focused Ultrasound,” 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210.
Sassen, Sander, “ATI's R520 architecture, the new king of the hill?” http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages.
Seip, Ralf, et al., “Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fields,” IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993.
Seip, Ralf, et al., “Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound,” IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839.
Simon et al., “Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy,” Ultrasound in Med. & Biol. vol. 19, No. 2, pp. 123-125 (1993).
Smith, Nadine Barrie, et al., “Non-invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques”, 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3.
Surry et al., “Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging,” Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49.
Syka J. E. P. et al., “Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectometry,” Proceedings of the National Academy of Sciences of USA, National Academy of Aceince, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533.
Talbert, D. G., “An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays,” UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67.
Tata et al., “Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions,” American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555.
Ueno, S., et al., “Ultrasound Termometry in Hyperthermia”, 1990 Ultrasonic Symposium, pp. 1645-1652.
Wang, H., et al., “Limits on Focused Ultrasound for Deep Hyperthermia”, 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3.
Wasson, Scott, “NVIDIA's GeForce 7800 GTX graphics processor Power MADD,” http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages.
White et al “Selective Creating of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy,” Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1.
Related Publications (1)
Number Date Country
20130072826 A1 Mar 2013 US
Provisional Applications (1)
Number Date Country
60616755 Oct 2004 US
Continuations (2)
Number Date Country
Parent 13444336 Apr 2012 US
Child 13679430 US
Parent 11163151 Oct 2005 US
Child 13444336 US